Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Hospira

- PMLiVE

Sangamo surges on data for haemophilia A gene therapy

After recent setbacks, news lifts shares

- PMLiVE

Novartis bolsters anti-inflammatory R&D with $1.6bn IFM Tre buy

Acquires its portfolio of NLRP3 targeting drugs

- PMLiVE

FDA approves Novartis’ next-gen MS drug Mayzent

Drug reduces risk of disease progression

- PMLiVE

Trump takes aim at Obamacare with repeal move

Aims to dismantle the programme

- PMLiVE

Novo uses voucher for speedy answer on oral semaglutide

Oral version of Ozempic could be diabetes market leader

- PMLiVE

Amgen, Servier heart failure drug clears trial hurdle

Drug could be a blockbuster - if it hits key endpoints

- PMLiVE

Pfizer hedges bets on gene therapy deal

Company not splashing out like Roche's Spark purchase

- PMLiVE

Francis exits Sandoz, reigniting spinoff rumours

Novartis says no such plans at present

- PMLiVE

J&J’s Spravato breaks depression drought at FDA

The esketamine nasal spray is the first new-mechanism antidepressant to be licensed in decades

- PMLiVE

Trump’s Brexit trade plan is bad for NHS, say campaigners

People’s Vote claims US wants to end NHS’ current regime of controlling drug costs

- PMLiVE

Novartis back in the spotlight over Trump/Cohen links

Cohen said the fee intended to get him to work as a lobbyist

- PMLiVE

Novartis in-licenses Akcea’s novel cardiovascular therapy

Lp(a) targeting therapy could treat millions

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links